Atara Biotherapeutics (ATRA) announced that a Type A meeting with the FDA has been scheduled to discuss the complete response letter, or CRL, to the biologics license application for tabelecleucel held by its partner Pierre Fabre Pharmaceuticals. Pierre Fabre Pharmaceuticals, with Atara’s support, will meet with the agency to collaboratively address the points from the CRL and enable a resubmission with the additional efficacy data that has been collected since the original BLA submission.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRA: